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The growing numbers of allogeneic hematopoietic stem cell trans-
plant (HSCT) survivors deserve a study of late effects. We analyzed
48 long term (range 10-16 years) survivors who underwent alloge-
neic HSCT at the NIH between 1993 and 2000. Their median age
at HSCTwas 35 years and the current median age is 49 years. There
were 20 males and 28 females. Forty-two patients received high dose
total body irradiation while the rest received reduced intensity con-
ditioning. Underlying diagnoses were CML (30), MDS/CMMoL
(7), AML (5), CLL (2), Myeloma (2), Severe Aplastic Anemia (1)
and ALL (1). Currently 38 patients are alive in complete remission,
4 alive with molecular recurrence of CML but 6 have died (2 of sec-
ond malignancy, one each of relapse, sepsis, CVA and multiorgan
failure). Health Related Quality of Life (HRQOL) analysis using
the the SF-36 scale found no significant difference in physical or
mental health between long term survivors overall and the U.S. gen-
eral population. Nevertheless, a subset of survivors reporting symp-
tom distress had lower HRQOL. Since immune dysfunction
underlies many late effect complications, we analyzed immune re-
constitution. Quantitative immunoglobulins for survivors were in
the normal range for the population as were absolute lymphocyte
counts (ALC), total CD31, CD31CD41, CD31CD81, CD191
and NK cells. Samples from 15 long term survivors were then com-
pared to current samples from their sibling donors and no quantita-
tive differences were observed in absolute lymphocyte counts (ALC),
total CD31, CD31CD41, CD31CD81, CD191 and NK cells.
However there was a significant expansion in the Treg (CD251/
CD41/FoxP31) compartment (p5 0.02), accompanied by a decline
in naive T cells (CD45RA1/CD271) (p\0.003) and recent thymic
emigrants (TREC1) (p\0.05) in survvors compared to their sibling
donors. T cell receptor repertoire analysis showed that there was no
significant difference in total complexity score of TCR-Vb diversity
between the patients and their donors, although TCR-Vb subfamily
spectratyping profiles showed divergence between patients and do-
nors with both gain and loss of clonotypes. In conclusion, survivors
in their second decade tend to remain vulnerable with disproportion-
ate mortality from diverse causes. Their QOL is typically excellent
but a small subset do experience persistent symptom distress. Im-
mune parameters, even 10 years postHSCT, are not completely nor-
mal and reflect impaired thymopoiesis and repertoire divergence.229
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Chronic graft-versus-host disease (GVHD) threatens patient-re-
ported quality of life (QOL) after allogeneic hematopoietic cell
transplantation. However, the sensitivity of serially assessed chronic
GVHD severity to change inQOL has not been determined.We ex-
amined the sensitivity of changes in chronic GVHD severity (deter-
mined separately by NIH consensus severity criteria, physician-
assessed severity, and patient-reported chronic GVHD severity) to
changes inQOL asmeasured with the SF-36 and FACT instrumentsS238in a prospectively assembled multi-center cohort of chronic GVHD
affected HCT recipients. A total of 341 individual adult (median age
52, range 19 – 79) patients (182 incident, 159 prevalent) from 6
transplant centers contributed data to an analysis encompassing
917 total visits. Chronic GVHD involvement most commonly in-
cluded skin (56%), oral (53%), ocular (55%), and hepatic (39%)
manifestations. On follow up, the majority had unchanged chronic
GVHD severity. However, follow up visits demonstrated improve-
ment (NIH 16%, physician 20%, patient 22%), or rather worsening
(NIH 17%, physician 14%, patient 16%) in others. Subjects with
complete or with missing data had similar clinical characteristics, ex-
cepting that those without missing data were more likely to have
a college or post-graduate degree (p 5 0.007). Univariable analysis
accounting for repeated observations was performed to examine
the relationship between change in chronic GVHD severity and
change in QOL. Multivariable analysis was performed considering
patient socio-demographic, disease, and transplantation covariates.
Conclusions discerned in univariable analysis persisted: Change in
NIH severity was not sensitive to change in QOL. Change in physi-
cian-assessed severity was sensitive to changes in SF-36 MCS (men-
tal component summary), and FACT-TOI (trial outcome index),
FACT-Total, and FACT-BMT (BMT subscale). Change in pa-
tient-reported severity was sensitive to changes in all QOL outcomes
(p\ 0.001 for each). These data demonstrate that NIH and physi-
cian determined chronic GVHD severity assessment do not capture
the full symptomburden experienced by chronicGVHDaffected pa-
tients. The data support the incorporation of patient-reported
chronic GVHD severity in the evaluation of severity change and
therapeutic response in the conduct of clinical trials as well as routine
clinical practice for those affected by chronic GVHD.230
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Introduction: Squamous cell carcinoma (SCC) of the oral cavity or
esophagus is a common secondary cancer after allogeneic hemato-
poietic stem cell transplantation (allo-HCT). As different from
oral SCC, diagnosis of esophageal carcinoma upon clinical symp-
toms is relatively late and mostly fatal. Thus, early detection of
esophageal carcinoma is highly desired. Previous studies reported
that human papillomavirus (HPV) infection is correlated with devel-
oping oral SCC after HCT. HPV infection is well documented as
a causative organism of cervical or oral SCC. Besides, several studies
have shown that the expression of p16 in biopsy specimens is associ-
ated withHPV infection in cervical SCC and is also found in precan-
cerous states such as intraepithelial neoplasia, dysplasia and
koilocytic change. In the gynecology field, p16 staining is commonly
used for biomarkers of HPV infection.
Purpose and Methods: To clarify the correlation between expres-
sion of p16 and the development of esophageal carcinoma after
allo-HCT, 48 patients who survived for at least 1 year after HCT
were enrolled in this study. They were examined by endoscopy and
Lugol staining. If Lugol’s voiding lesion was found, biopsy and the
staining for p16 were performed.
Result: The median age was 45 years, and the median duration of
follow-up was 7.3 years. In one patient, a tumor found by endoscopy
was diagnosed as SCC. Of the remaining 47 patients who received
Lugol staining, 22 showed unstained areas and were examined by bi-
opsy. Expression of p16 was found in 15 of the 22 patients. Among
fifteen p16- positive patients, precancerous lesions such as intraepi-
thelial neoplasia (n 5 1), dysplasia (n 5 1) and koilocytic changes (n
5 5) were found. On the other hand, among seven p16-negative pa-
tients, only a koilocytic change was found in one patient. Chronic
GVHD and administration of immunosuppressin at the examination
were significantly related with p16 positivity.
